In summary, tirzepatide is an innovative therapeutic agent with a dual mechanism of action that provides a potent tool for managing T2D and obesity
Using Dandelion Healths GLP-1 Data Library, we conducted a study to compare outcomes for patients who have taken a GLP-1 and a matched cohort of patients who have never taken a GLP-1, but were very similar clinically, to evaluate whether GLP-1 use in the real world is as effective as results reported in clinical trials
Sometimes, manufacturer shortages force a treatment gap beyond your control
Mechanisms of weight loss are multifactorial and independent of diabetes status, as seen in the SCALE Obesity and Prediabetes Study Group trial of GLP1RA in obese patients without diabetes, who lost 5.6 kg more weight than placebo (50)
With the growing popularity of glucagon-like peptide 1 receptor agonists (GLP-1 receptor agonists) like Wegovy, you may have seen advertisements for compounded semaglutide productsbut are these products exactly the same as Wegovy
Ask for follow-up labs and a concrete plan for lifestyle integration